GSK said late Wednesday that it agreed to settle a vast majority of lawsuits concerning its discontinued heartburn medicine Zantac. "GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at ...
GSK Plc said it will pay as much as ... to pay more than $100 million to settle about 4,000 Zantac-related lawsuits. Pfizer agreed to settle more than 10,000 related cases, Bloomberg reported ...
or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer ...
Oct 9 (Reuters) - GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...
After protracted legal battling, GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
GSK earlier this month agreed to pay $2.3 billion to end lawsuits alleging that Zantac ... deal in principle to pay $70 million to settle a separate Zantac case with US laboratory Valisure.
(Sharecast News) - GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of markets on Wednesday, the pharmaceuticals firm said it ...
(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced ...